JAK3-IN-6

JAK3-IN-6，Cas号 1443235-95-7，纯度: 99.48%，是 JAK3 的一个有效的、选择性的、不可逆的抑制剂，其 IC50 值为 0.15 nM。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

JAK3-IN-6

所属分类

抑制剂

目录号

HY-101976

获取报价

猜你喜欢

产品描述
产品组分
文件资源
营销中心
注意事项
FAQ
文献追踪

JAK3-IN-6 是 JAK3 的一个有效的、选择性的、不可逆的抑制剂，其 IC₅₀ 值为 0.15 nM。

生物活性

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

IC₅₀ & Target

JAK3

0.15 nM (IC₅₀)

体外研究
(In Vitro)

JAK3-IN-6 (compound 2), a potent inhibitor of JAK3 (0.15 nM) is 4300-fold selective for JAK3 over JAK1 in enzyme assays, 67-fold (IL-2 vs. IL-6) or 140-fold (IL-2 vs. EPO or GMCSF) selective in cellular reporter assays and >35-fold selective in human PBMC assays (IL-7 vs. IL-6 or GMCSF). Irreversible JAK3-IN-6 with a JAK1 selective inhibitor 3 (JAK1: 0.96 nM, JAK2: 14 nM, JAK3: >1500 nM, TYK2: 10 nM) are cross titrated to determine if there is an additive or synergistic effect of co-inhibiting JAK1 and JAK3 enzymes on IL-7 signaling in CD3+, CD4+ PBMCs. As shown, the predicted levels of pSTAT5 inhibition based on addition of JAK1 and JAK3 inhibition are very close to the measured effects of cross titrating each compound, demonstrating that there is an additive effect but no synergistic effect of inhibiting JAK1 and JAK3 on blocking STAT5 phosphorylation. Furthermore inhibition of either JAK1 or JAK3 alone is sufficient to fully inhibit pSTAT5^[2].

分子量

350.37

Formula

C₁₉H₁₈N₄O₃

CAS 号

1443235-95-7

性状

固体

颜色

White to light yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

产品组分

内容	型号	规格	储存温度
JAK3-IN-6	T3043-01	1mg	-20°C
JAK3-IN-6	T3043-02	5mg	-20°C
JAK3-IN-6	T3043-03	10mg	-20°C
JAK3-IN-6	T3043-04	25mg	-20°C
JAK3-IN-6	T3043-05	50mg	-20°C
JAK3-IN-6	T3043-06	100mg	-20°C
操作手册	1	1	常温

文件资源

营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
1.Lin Y, et al. Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. J Clin Invest. 2023 Aug 1;133(15):e162201.

2.Zhu H, et al. Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition. Front Immunol. 2021 Jul 22;12:714943.

3.Song HT,et al. Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells. Microvasc Res. 2020 Nov;132:104060.